Shanghai Haihong Industrial Group Chaohu Jinchen Pharmaceutica

The main purpose of the study is to evaluate the pharmacokinetics of the test preparation paroxetine hydrochloride enteric-coated sustained-release tablets 25 mg and the reference preparation paroxetine hydrochloride enteric-coated sustained-release tablets (trade name: Seroxetine®CR) 25 mg in healthy adult subjects, and to evaluate the oral bioequivalence of the two preparations in the fasting/postprandial state. Secondary purpose of the study is to evaluate the safety of the test preparation paroxetine hydrochloride enteric-coated sustained-release tablets and the reference preparation paroxetine hydrochloride enteric-coated sustained-release tablets (trade name: Seroxetine®CR) in healthy adult subjects.

The main purpose of the study is to evaluate the pharmacokinetics of the test preparation fluvastatin sodium sustained-release tablets 80 mg and the reference preparation fluvastatin sodium sustained-release tablets (Lescol®) 80 mg in healthy adult subjects, and to evaluate the bioequivalence of the two preparations taken orally in the fasting/postprandial state. Secondary purpose of the study is to observe the safety of the test preparation fluvastatin sodium sustained-release tablets and the reference preparation fluvastatin sodium sustained-release tablets (Lescol®) in healthy people.

Main research purpose: According to the relevant provisions of bioequivalence test, metformin empagliflozin tablets (trade name: SYNJARDY, specification: 500mg+5mg) with BOEHRINGER INGEL HEIM PTY LTD as the licensee were selected as the reference preparation, and the test preparation metformin empagliflozin tablets (specification: 500mg+5mg) produced and provided by Shanghai Haihong Industrial (Group) Chaohu Jinchen Pharmaceutical Co., Ltd. were subjected to human bioequivalence test for fasting and postprandial administration, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary research purpose: To observe the safety of oral administration of the test preparation metformin empagliflozin tablets (specification: 500mg+5mg) and the reference preparation metformin empagliflozin tablets (trade name: SYNJARDY, specification: 500mg+5mg) in healthy subjects.